AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES FORMULATION, DEVELOPMENT AND CHARACTERIZATION OF SUSTAINED RELEASE BILAYERED TABLET OF VALSARTAN AND PIOGLITAZONE HCl
ABSTRACT Valsartan is a drug used to treat high blood pressure and congestive heart failure. Pioglitazone is a drug that reduces the amount of glucose (sugar) in the blood. It is in a class of anti-diabetic drugs called thiazolidinediones that are used in the treatment of type 2 diabetes. The main objectives of sustained release bilayered tablet of Valsartan and Pioglitazone HCl is that antihypertensive and antidiabetic both drugs can be given in one dosage form. It gives sustained release of both drugs upto 12hr and decrease the chances of Myocardial Infraction which is due to Pioglitazone HCl. In the present research the comparative study between HPMC K4M, HPMC K15M & HPMC K100M was performed. Sustained release bilayered tablets were prepared by different concentration of polymers (45%, 55%, 65%). The powder mixture of Valsartan and other ingredients, Pioglitazone HCl and other ingredients were evaluated for various physical properties such as bulk density, tapped density, angle of repose, carr's index and hausner's ratio. The bilayered tablets were evaluated by different parameters such as hardness, friability, weight variation, drug content uniformity, Swelling Index, and In vitro drug release. The optimized formulation (F9) containing 65% HPMC K15M in Valsartan layer and 65% HPMC K100M in Pioglitazone HCl layer shows in vitro drug release upto 12 hrs
